The Therapeutic Potential of Nanobodies
来源期刊:BiodrugsDOI:10.1007/s40259-019-00392-z
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
来源期刊:BiodrugsDOI:10.1007/s40259-019-00333-w
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
来源期刊:BiodrugsDOI:10.1007/s40259-019-00367-0
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
来源期刊:BiodrugsDOI:10.1007/s40259-019-00370-5
Evolution of the EU Biosimilar Framework: Past and Future
来源期刊:BiodrugsDOI:10.1007/s40259-019-00377-y
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
来源期刊:BiodrugsDOI:10.1007/s40259-019-00368-z
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review
来源期刊:BioDrugsDOI:10.1007/s40259-019-00347-4
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
来源期刊:BiodrugsDOI:10.1007/s40259-019-00394-x
Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
来源期刊:BiodrugsDOI:10.1007/s40259-019-00344-7
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
来源期刊:BiodrugsDOI:10.1007/s40259-019-00350-9
CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms
来源期刊:BioDrugsDOI:10.1007/s40259-019-00384-z
Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
来源期刊:BioDrugsDOI:10.1007/s40259-019-00355-4
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting
来源期刊:BiodrugsDOI:10.1007/s40259-019-00345-6
Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment
来源期刊:BiodrugsDOI:10.1007/s40259-019-00362-5
Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries
来源期刊:BioDrugsDOI:10.1007/s40259-019-00359-0
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications
来源期刊:BioDrugsDOI:10.1007/s40259-019-00382-1
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
来源期刊:BiodrugsDOI:10.1007/s40259-019-00363-4
Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis
来源期刊:BioDrugsDOI:10.1007/s40259-019-00376-z
An Efficient Development Paradigm for Biosimilars
来源期刊:BiodrugsDOI:10.1007/s40259-019-00371-4
PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen®): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
来源期刊:BiodrugsDOI:10.1007/s40259-019-00343-8
Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics
来源期刊:BioDrugsDOI:10.1007/s40259-019-00389-8
Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis
来源期刊:BioDrugsDOI:10.1007/s40259-019-00356-3
Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar
来源期刊:BioDrugsDOI:10.1007/s40259-019-00349-2
A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males
来源期刊:BioDrugsDOI:10.1007/s40259-019-00340-x
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
来源期刊:BiodrugsDOI:10.1007/s40259-019-00393-y
Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
来源期刊:BioDrugsDOI:10.1007/s40259-019-00358-1
Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar
来源期刊:BioDrugsDOI:10.1007/s40259-019-00334-9
Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
来源期刊:BiodrugsDOI:10.1007/s40259-019-00373-2
Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
来源期刊:BioDrugsDOI:10.1007/s40259-019-00357-2
Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP)
来源期刊:BiodrugsDOI:10.1007/s40259-019-00380-3
Biosimilars: A Value Proposition
来源期刊:BioDrugsDOI:10.1007/s40259-019-00360-7
The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks
来源期刊:BioDrugsDOI:10.1007/s40259-019-00369-y
Comment on: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”
来源期刊:BioDrugsDOI:10.1007/s40259-019-00383-0
Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
来源期刊:BiodrugsDOI:10.1007/s40259-019-00353-6
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
来源期刊:BiodrugsDOI:10.1007/s40259-019-00381-2
Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine
来源期刊:BioDrugsDOI:10.1007/s40259-019-00366-1
Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis
来源期刊:BioDrugsDOI:10.1007/s40259-019-00378-x
In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study
来源期刊:BioDrugsDOI:10.1007/s40259-019-00385-y
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
来源期刊:BiodrugsDOI:10.1007/s40259-019-00375-0
LA-EP2006: A Pegfilgrastim Biosimilar
来源期刊:BioDrugsDOI:10.1007/s40259-019-00348-3
Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals
来源期刊:BiodrugsDOI:10.1007/s40259-019-00341-w
Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy
来源期刊:BioDrugsDOI:10.1007/s40259-019-00365-2
Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product
来源期刊:BiodrugsDOI:10.1007/s40259-019-00386-x
Author’s Reply to Puértolas-Tena and Pérez-Surio: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”
来源期刊:BioDrugsDOI:10.1007/s40259-019-00379-w
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
来源期刊:BiodrugsDOI:10.1007/s40259-019-00390-1
In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima®) Following Preparation for Intravenous Infusion and Storage
来源期刊:BioDrugsDOI:10.1007/s40259-019-00336-7
Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study
来源期刊:BioDrugsDOI:10.1007/s40259-019-00396-9
Delivering on the Promise of Biosimilars
来源期刊:BioDrugsDOI:10.1007/s40259-019-00388-9
Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?
来源期刊:BiodrugsDOI:10.1007/s40259-019-00374-1
Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity
来源期刊:BioDrugsDOI:10.1007/s40259-019-00391-0